Individualized risk components guiding antipsychotic delivery in patients with a clinical high risk of psychosis: application of a risk calculator
- 17 February 2021
- journal article
- research article
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 52 (15), 3412-3421
- https://doi.org/10.1017/s0033291721000064
Abstract
Background Antipsychotics are widely used for treating patients with psychosis, and target threshold psychotic symptoms. Individuals at clinical high risk (CHR) for psychosis are characterized by subthreshold psychotic symptoms. It is currently unclear who might benefit from antipsychotic treatment. Our objective was to apply a risk calculator (RC) to identify people that would benefit from antipsychotics. Methods Drawing on 400 CHR individuals recruited between 2011 and 2016, 208 individuals who received antipsychotic treatment were included. Clinical and cognitive variables were entered into an individualized RC for psychosis; personal risk was estimated and 4 risk components (negative symptoms-RC-NS, general function-RC-GF, cognitive performance-RC-CP, and positive symptoms-RC-PS) were constructed. The sample was further stratified according to the risk level. Higher risk was defined based on the estimated risk score (20% or higher). Results In total, 208 CHR individuals received daily antipsychotic treatment of an olanzapine-equivalent dose of 8.7 mg with a mean administration duration of 58.4 weeks. Of these, 39 (18.8%) developed psychosis within 2 years. A new index of factors ratio (FR), which was derived from the ratio of RC-PS plus RC-GF to RC-NS plus RC-CP, was generated. In the higher-risk group, as FR increased, the conversion rate decreased. A small group (15%) of CHR individuals at higher-risk and an FR >1 benefitted from the antipsychotic treatment. Conclusions Through applying a personal risk assessment, the administration of antipsychotics should be limited to CHR individuals with predominantly positive symptoms and related function decline. A strict antipsychotic prescription strategy should be introduced to reduce inappropriate use.This publication has 40 references indexed in Scilit:
- Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agentsMolecular Psychiatry, 2012
- Neuropsychology of the Prodrome to Psychosis in the NAPLS ConsortiumRelationship to Family History and Conversion to PsychosisNeuropsychology of Prodrome to PsychosisArchives of General Psychiatry, 2010
- Basic Symptoms and Ultrahigh Risk Criteria: Symptom Development in the Initial Prodromal StateSchizophrenia Bulletin, 2008
- The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and ValidityAmerican Journal of Psychiatry, 2008
- The MATRICS Consensus Cognitive Battery, Part 2: Co-Norming and StandardizationAmerican Journal of Psychiatry, 2008
- Mapping the Onset of Psychosis: The Comprehensive Assessment of At-Risk Mental StatesAustralian & New Zealand Journal of Psychiatry, 2005
- The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative reviewJournal of Psychopharmacology, 2005
- Cognitive therapy for the prevention of psychosis in people at ultra-high riskThe British Journal of Psychiatry, 2004
- Prodromal Assessment With the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: Predictive Validity, Interrater Reliability, and Training to ReliabilitySchizophrenia Bulletin, 2003
- Prospective Diagnosis of the Initial Prodrome for Schizophrenia Based on the Structured Interview for Prodromal Syndromes: Preliminary Evidence of Interrater Reliability and Predictive ValidityAmerican Journal of Psychiatry, 2002